You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 20, 2025

CLINICAL TRIALS PROFILE FOR NIZORAL A-D


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Nizoral A-d

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT01110330 ↗ An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot Terminated Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 2007-07-01 The purpose of this study is to determine if a new formulation of ketoconazole 2% cream is as effective as a current formulation of ketoconazole 2% cream (Nizoral) compared with placebo in treating patients with Tinea pedis, a skin infection commonly known as "athlete's foot" that is caused by a kind of mold called a fungus.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Nizoral A-d

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002855 ↗ Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer Completed National Cancer Institute (NCI) Phase 3 1996-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone therapy versus androgen suppression alone as initial therapy in patients with prostate cancer that is metastatic or that cannot be removed surgically.
NCT00002855 ↗ Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer Completed M.D. Anderson Cancer Center Phase 3 1996-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone therapy versus androgen suppression alone as initial therapy in patients with prostate cancer that is metastatic or that cannot be removed surgically.
NCT00003084 ↗ Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer Completed National Cancer Institute (NCI) Phase 2 1997-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy consisting of paclitaxel, etoposide, and estramustine as compared with ketoconazole plus doxorubicin, vinblastine, and estramustine in treating patients with prostate cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nizoral A-d

Condition Name

Condition Name for Nizoral A-d
Intervention Trials
Prostate Cancer 8
Tinea Pedis 5
Type 2 Diabetes 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nizoral A-d
Intervention Trials
Prostatic Neoplasms 11
Tinea Pedis 5
Tinea 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nizoral A-d

Trials by Country

Trials by Country for Nizoral A-d
Location Trials
United States 68
Australia 8
New Zealand 4
Brazil 2
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nizoral A-d
Location Trials
Texas 9
California 7
Nebraska 4
Florida 4
New York 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nizoral A-d

Clinical Trial Phase

Clinical Trial Phase for Nizoral A-d
Clinical Trial Phase Trials
Phase 4 1
Phase 3 6
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nizoral A-d
Clinical Trial Phase Trials
Completed 15
Terminated 10
Recruiting 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nizoral A-d

Sponsor Name

Sponsor Name for Nizoral A-d
Sponsor Trials
National Cancer Institute (NCI) 7
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center 3
GlaxoSmithKline 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nizoral A-d
Sponsor Trials
Other 35
Industry 17
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Ketoconazole: Clinical Trials, Market Analysis, and Projections

Introduction

Ketoconazole, commonly known by the brand name Nizoral, is a versatile antifungal medication with a wide range of applications. This article will delve into the current state of clinical trials, market analysis, and future projections for ketoconazole.

Clinical Trials and Medical Uses

Treatment of Fungal Infections

Ketoconazole has been a staple in the treatment of fungal infections for several decades. However, its oral formulations were suspended in 2013 due to the risk of liver injury. Despite this, topical forms of ketoconazole, such as shampoos and creams, remain widely used for treating fungal infections like seborrheic dermatitis, dandruff, and tinea infections[1][5].

Cushing’s Syndrome

Ketoconazole HRA is specifically indicated for the treatment of endogenous Cushing’s syndrome in adults and adolescents above 12 years. It works by blocking the production of cortisol in the adrenal glands, thereby relieving the symptoms of the disease. Clinical data from over 800 patients have shown that ketoconazole can normalize urine cortisol levels in 43-80% of patients[1].

EGFR Inhibitor-Induced Rash

An ongoing clinical trial is investigating the use of topical ketoconazole to treat rash induced by EGFR inhibitors in cancer patients. This phase I trial aims to assess the safety and efficacy of ketoconazole in reducing symptoms related to EGFR inhibitor therapy[4].

Market Analysis

Current Market Size and Growth

The ketoconazole market was valued at USD 782.3 million in 2023 and is projected to reach USD 1200 million by 2031, growing at a CAGR of 4.6% from 2024 to 2031. This growth is driven by the increasing prevalence of fungal infections, rising demand for over-the-counter antifungal medications, and the expanding pharmaceutical sector[5].

Geographical Distribution

North America dominated the ketoconazole market in 2022, driven by factors such as the availability of innovative products, growing health awareness, and a rising urban population. Other significant regions include Europe, Asia-Pacific, and the Rest of the World[2][5].

Application Segments

The market is segmented into various applications, including antifungal treatments, hair loss treatments, and others. The hair loss segment, particularly for conditions like dandruff and seborrheic dermatitis, is expected to grow with the highest CAGR during the forecast period due to rising cases of hair loss and the demand for safe and effective haircare medicines[2][5].

Key Players

Major players in the ketoconazole market include Mylan Inc., Almirall, S.A, Johnson & Johnson Services, Inc., Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Strides Pharma Science Limited, and ANI Pharmaceuticals, among others[2][3].

Market Projections

Forecasted Growth

The ketoconazole market is expected to grow steadily due to several factors:

  • Increasing Prevalence of Fungal Infections: Especially in tropical and subtropical areas, the need for potent antifungal medications is on the rise.
  • Expanding Pharmaceutical Sector: Continuous research and development of new formulations are enhancing the market potential.
  • Rising Demand for Over-the-Counter Antifungal Medications: Increased awareness and accessibility of over-the-counter antifungal drugs are driving market growth.
  • Growing Prevalence of Skin Diseases: Conditions like dandruff and seborrheic dermatitis, which can be treated with ketoconazole-based treatments, are becoming more common[5].

Recent Developments

ANI Pharmaceuticals recently announced the FDA approval and launch of Ketoconazole Shampoo, 2%, a generic version of the reference listed drug Nizoral. This launch is expected to further boost the market by providing another accessible option for patients[3].

Safety and Monitoring

Liver Function Monitoring

For patients using ketoconazole, especially for Cushing’s syndrome, regular monitoring of liver function is crucial. Blood tests should be conducted before treatment and regularly for the following six months, with weekly checks for one month when the dose is increased. Treatment must be stopped if liver enzyme levels exceed three times the normal maximum or if symptoms suggestive of liver problems occur[1].

Risk Management Plan

A risk management plan has been developed to ensure the safe use of Ketoconazole HRA. This plan includes safety information in the summary of product characteristics and the package leaflet, outlining precautions for healthcare professionals and patients[1].

Key Takeaways

  • Versatile Applications: Ketoconazole is used in treating fungal infections, Cushing’s syndrome, and potentially EGFR inhibitor-induced rash.
  • Market Growth: The ketoconazole market is projected to grow at a CAGR of 4.6% from 2024 to 2031.
  • Geographical Dominance: North America currently dominates the market, with significant contributions from Europe and Asia-Pacific.
  • Safety Considerations: Regular liver function monitoring is essential for patients using ketoconazole.
  • Recent Developments: FDA approval of new ketoconazole products, such as ANI Pharmaceuticals’ Ketoconazole Shampoo, 2%, is expanding market options.

FAQs

What are the primary uses of ketoconazole?

Ketoconazole is primarily used to treat fungal infections, Cushing’s syndrome, and it is also being investigated for treating EGFR inhibitor-induced rash.

Why was the oral formulation of ketoconazole suspended?

The oral formulation of ketoconazole was suspended in 2013 due to the risk of liver injury.

What is the projected growth rate of the ketoconazole market?

The ketoconazole market is expected to grow at a CAGR of 4.6% from 2024 to 2031.

Which region dominates the ketoconazole market?

North America currently dominates the ketoconazole market.

What are the key factors driving the growth of the ketoconazole market?

The growth is driven by the increasing prevalence of fungal infections, rising demand for over-the-counter antifungal medications, and the expanding pharmaceutical sector.

What safety precautions are necessary when using ketoconazole?

Regular monitoring of liver function is crucial, and treatment should be stopped if liver enzyme levels exceed three times the normal maximum or if symptoms suggestive of liver problems occur.

Sources

  1. European Medicines Agency. Ketoconazole HRA | European Medicines Agency (EMA).
  2. GII Research. Ketoconazole Market: Current Analysis and Forecast (2023-2030).
  3. ANI Pharmaceuticals. ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2%.
  4. Mayo Clinic. Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash.
  5. Market Research Intellect. Ketoconazole Market Size, Share and Forecast to 2031.
Last updated: 2025-01-03

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.